Recent progress has been made in use of blood biomarkers for the early recognition of persons at high risk for development of AD, especially measurement of phosphorylated tau (P-tau) species such as P-tau181, P-tau217, and P-tau231 (Verde, 2022). This evidence concerns the gene MAPT and Alzheimer disease.